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Abstract
There is an urgency to find new treatments for the devastating epidemic of diabetes. Pancreatic b-cells viability and function
are impaired in the two most common forms of diabetes, type 1 and type 2. Regeneration of pancreatic b-cells has been
proposed as a potential therapy for diabetes. In a preliminary study, we screened a collection of marine products for b-cell
proliferation. One unique compound (epoxypukalide) showed capability to induce b-cell replication in the cell line INS1 832/
13 and in primary rat cell cultures. Epoxypukalide was used to study b-cell proliferation by [3H]thymidine incorporation and
BrdU incorporation followed by BrdU/insulin staining in primary cultures of rat islets. AKT and ERK1/2 signalling pathways
were analyzed. Cell cycle activators, cyclin D2 and cyclin E, were detected by western-blot. Apoptosis was studied by TUNEL
and cleaved caspase 3. b-cell function was measured by glucose-stimulated insulin secretion. Epoxypukalide induced 2.5-
fold increase in b-cell proliferation; this effect was mediated by activation of ERK1/2 signalling pathway and upregulation of
the cell cycle activators, cyclin D2 and cyclin E. Interestingly, epoxypukalide showed protection from basal (40% lower
versus control) and cytokine-induced apoptosis (80% lower versus control). Finally, epoxypukalide did not impair b-cell
function when measured by glucose-stimulated insulin secretion. In conclusion, epoxypukalide induces b-cell proliferation
and protects against basal and cytokine-mediated b-cell death in primary cultures of rat islets. These findings may be
translated into new treatments for diabetes.
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Introduction
Diabetes is one of the most devastating diseases of our era. The
most common forms are type 1 and type 2 diabetes. b-cell mass
decreases approximately by 70–100% in type 1 diabetes and up to
65% in type 2 diabetes. Both forms of the disease display increased
b-cell apoptosis [1,2].
Finding therapeutic targets and molecules that preserves and/or
enhances functional beta-cell mass is essential in the long-term
treatment of diabetes. It is known that adult pancreatic b-cells, in
rodents and humans, are generated from the proliferation of
differentiated beta-cells [3,4]. Some growth factors have been
shown to induce b-cell proliferation in vitro and in vivo, among
them HGF (hepatocyte growth factor), PL (placental lactogen) and
PTHrP (Parathyroid hormone related protein) have also shown
enhancement of b-cell survival [5].
Classical signalling pathways involved in beta-cell proliferation
comprise PI3K/AKT, ERK1/2, PKC and JAK2/STA5 [5].
Activation of these intracellular effectors ends on the regulation of
the proteins that control G1/S interphase of the cell cycle. Among
all the proteins that regulate this interphase, pRb is the key
checkpoint gatekeeper. The complexes that regulate pRb phos-
phorylation (and its inactivation to allow cell cycle progression) are
cdk4/cyclin D and cdk2/cyclinE [6]. Both, cyclin D2 and cyclin E
have been found to have a relevant role in several models of b-cell
proliferation [5,7,8,9,10,11,12,13], being essential to induce b-cell
replication.
Epoxypukalide was reported by Schmitzs group in 1984 by the
first time [14], they purified it from the gorgonian Leptogorgia
setacea. Epoxypukalide and other furanocembranolides were
identified in 2007 by Dorta et al. [15] who searched for marine
natural products in benthic species around the Isthmus of Panama.
Finally Grote et al. [16] described a group of furanocembranoids
isolated from the soft coral Sinularia asterolobata, being one of them
epoxypukalide. They studied the cytotoxic and anti-proliferative
effect of those compounds, reporting that epoxypukalide did not
inhibit HeLa (human epithelial carcinoma) cell proliferation nor
produces cytotoxicity in the cell lines L-929 (murine fibrosarcoma)
or K-562 (human erythroleukemic cell line) [16].
In the current report, we demonstrate a proliferative effect of
epoxypukalide on primary cultures of rat b-cells, in parallel to a
protective effect on b-cell death while preserving b-cell function.
Epoxypukalide-induced b-cell proliferation is mediated by ERK1/
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e52862
2 activation and targets cyclin D2 and cyclin E. Taken together
these data support a potential use of epoxypukalide in the
treatment of diabetes.
Methods
Ethical Approval
Experimental procedures were approved by the Animal Care
and Use Committee of the University of Cadiz in accordance with
the Guidelines for Care and Use of Mammals in Research
(European Commission Directive 86/609/CEE and Spanish
Royal Decree 1201/2005).
Cell Culture
INS-1 832/13 cells were grown at 37uC and 5% CO2 in a
humidified atmosphere. INS-1 culture medium was RPMI-1640
with 2 mmol/l L-glutamine supplemented with 11 mmol/l D-
glucose, 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml
streptomycin, 10 mmol/l HEPES, 1 mmol/l sodium pyruvate,
and 50 mmol/l b-mercaptoethanol.
Rat islets were isolated from 2 months old male Wistar rats
provided by Animal Production and Experimentation Service
(SEPA, University of Ca´diz) by a standard procedure and
incubated at 37uC and 5% CO2 in a humidified atmosphere.
Culture medium was RPMI-1640 with 2 mmol/l L-glutamine
supplemented with 5.5 mmol/l D-glucose, 10% fetal bovine
serum, 100 U/ml penicillin, and 100 mg/ml streptomycin.
Proliferation in INS-1 Cells
For the first screening, INS-1 832/13 cells were seeded at a
density of 20,000 cells per well in 96-well plates. Natural products
were assayed at a final concentration of 0.1 mM in culture medium
with 5.5 mM glucose. Proliferation was measured after 24 hours
by BrdU kit (Roche, Germany), following manufacturer’s instruc-
tions.
Proliferation in Rat Islets
Rat islets were isolated and incubated in serum free medium
with 0, 0.01, 0.1 and 1 mM epoxypukalide after an overnight
recovery. 24 hours later, 100 IEq (islet equivalent) per well were
seeded in 24-well plates with fresh medium without FBS
containing [3H]thymidine (1 mCi/well). [3H]thymidine incorpo-
ration was measured 24 h later; radioactivity was corrected for
protein levels measured by the BCA kit (Thermo Fisher, USA).
Results are expressed as percentage of counts per minute
incorporated per microgram of protein in control cells (100%).
To determine specific b-cell proliferation, isolated rat islets were
treated with medium without serum containing 0.1 mM epox-
ypukalide after an overnight recovery. 24 hours later, islets were
serum depleted and incubated with 1 ml/ml BrdU (Sigma-Aldrich,
USA). Islets were then incubated for 24 hours. Afterwards islets
were fixed with Bouins Solution (Sigma-Aldrich, USA) for 1 hour
and then with formalin until treated for paraffin blocks. 5 mm
sections were stained with rat anti-BrdU antibody (Abcam, UK)
and with guinea pig anti-Insulin antibody (Invitrogen, USA).
Fluorescence images of the sections were acquired using a
Olympus BX40 fluorescence axial microscope. The BrdU-positive
nuclei of beta cells and the total nuclei of beta cells were counted
manually with the assistance of the ImageJ software. At least 1000
insulin-positive cells for each preparation were counted.
Western-blot
Islets used to study signalling pathways activation (AKT and
ERK1/2) were treated for 0, 5, 15 or 30 minutes with 0.1 mM
epoxypulide after overnight recovery from islet isolation.
Islets used to study cell cycle proteins expression were treated for
24 h with 0.1 mM epoxypukalide after overnight recovery from
islet isolation.
After their treatment, islets were washed with PBS (phosphate-
buffered saline) and lysed in lysis buffer (125 mM Tris, pH 6.8,
2% SDS, 1 mM DTT and protease/phosphatase inhibitors). The
protein lysates were briefly sonicated and centrifuged for 1 minute
at the maximum speed. Proteins were measured by Micro BCA kit
(Thermo-Fisher, USA), run on a 10% EZ-Run Gel (Fisher
Scientific, USA) and then transferred to a PVDF Immobilon-P
membrane (Millipore, USA). Blots were incubated with the
following antibodies: anti-Phospho-AKT (Ser473) (Cell Signaling,
UK), anti-phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204)
(Cell Signaling, UK), anti-cyclin D1 (Invitrogen, USA), anti-cyclin
D2 (Invitrogen, USA), anti-cyclin D3 (Abcam, UK), anti-cyclin E
(Santa Cruz, USA), anti-cdk4 (Abcam, UK), anti-cdk2 (Santa
Cruz, USA) or anti-actin (Sigma, USA).
For cleaved caspase 3 western-blots, rat islets were treated with
cytokines mix (IL-1b, IFN-c and TNF-a) 1000 U/mL. Islets were
preincubated with epoxypukalide 0.01, 0.1 and 1 mM for 48 h.
Western-blot was performed as described above using anti-
cleaved-caspase 3 antibody (Cell Signaling, UK).
Beta-cell Death
5 mm sections obtained as explained above were used for
TUNEL-staining. DeadEnd Fluorometric Tunel System Kit
(Promega, USA) was used following manufacturer’s instructions.
TUNEL-positive/beta-cells were counted and represented as a
percentage of total number of beta-cells. Nuclei of beta cells were
counted manually with the assistance of the ImageJ software. At
least 1000 TUNEL-positive cells for each preparation were
counted.
Glucose-stimulated Insulin Secretion and Insulin Content
Secretion assays was performed on treated rat islets and their
controls. Islets were plated on cell culture inserts onto 24-well
plates at a density of 20 IEq groups in HEPES balanced salt
solution (HBSS) (114 mmol/l NaCl, 4.7 mmol/l KCl, 1.2 mmol/l
KH2PO4, 1.16 mmol/l MgSO4, 20 mmol/l HEPES, 2.5 mmol/l
CaCl2, 25.5 mmol/l NaHCO3, and 0.2% bovine serum albumin
[essentially fatty acid free], pH 7.2). Islets were washed twice in
1 ml HBSS with 2.2 mmol/l glucose followed by 10 minutes of
preincubation in 2 ml of the same buffer. Insulin secretion was
stimulated by using static incubation for 30 minutes in 1 ml of the
same buffer, followed by 30 minutes of incubation in HBSS
containing 22 mmol/l glucose. Secretion samples were measured
by ultra-sensitive rat insulin ELISA (Alpco Diagnostics, USA).
20 IEq by triplicate of each condition (control, 0.01, 0.1 and
1 mM epoxypukalide) were harvested after 24 h treatment. Insulin
was extracted using 1 mL of acid-ethanol (70% ethanol and 0.02%
HCl). Insulin was measured by rat insulin ELISA.
Statistics
Statistical analyses of data were performed by Student-t test
when two conditions were compared and ANOVA when more
than two conditions were compared. Data were expressed as mean
6 SD. P values ,0.05 were considered significant.
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Figure 1. Screening of a collection of marine natural products. INS-1 832/13 cells were preincubated with 0.1 mM of the seven
furanocembranolides (1–7) and proliferation was measured by BrdU incorporation as described in Methods section (N = 6). Proliferation was defined
as the fold change above untreated cells (1.0) Threshold was over 1.5-fold increase in proliferation (A). Chemical structure of the seven
furacembranolides (B).
doi:10.1371/journal.pone.0052862.g001
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Results
Screening of a Collection of Marine Natural Products
Seven furanocembranolides (Figure 1) obtained from the soft
coral Leptogorgia spp. [15] were screened for induction of b-cell
proliferation in the rat cell line INS-1 832/13. This group of
compounds was chosen from a larger collection of marine natural
products, after a preliminary screening, being the unique group of
compounds inducing beta-cell proliferation of the INS1 832/13
cells (data not shown). Cell proliferation was measured using BrdU
incorporation. Four products, epoxypukalide (1), pukalide (2), (Z)-
deoxypukalide (3) and leptolide (4), induced b-cell proliferation
over the threshold ($1.5-fold compared to control) (Figure 1).
Epoxypukalyde Induces b-cell Proliferation in Primary Rat
Islets
We used isolated rat islets to test ex-vivo the proliferative
capability of compounds 1–4. Proliferation was measured using
[3H]thymidine incorporation. Epoxypukalide (1) showed an
increase of 30% in proliferation compared to control, conversely
pukalide (2), leptolide (4) and (Z)-deoxypukalide (3) did not induce
proliferation in primary cell cultures (Figure 2A). Then, we
performed a dose response evaluation of epoxypukalide to test cell
proliferation, using concentrations from 0.01–1 mM. Only 0.1 mM
showed a significant increase in cell proliferation (Figure 2B).
Thus, for following experiments involving beta-cell proliferation
we have used 0.1 mM epoxypukalide. As a second approach and in
order to measure specific b-cell proliferation, we used BrdU
incorporation followed by insulin/BrdU staining to quantify
BrdU+insulin+ cells in respect to total insulin+ cells. Epoxypuka-
lide treatment showed 250% increased b-cell proliferation
compared to control cells (Figure 2C, D).
Activation of Signalling Pathways by Epoxypukalyde in
Primary Rat Islets
The analysis by western-blot of two of the most relevant
signalling pathways involved in b-cell proliferation indicated that
epoxypukalide did not activate AKT pathway (Figure 3A, B), but
ERK1/2 was activated within the first 30 minutes after treatment
(Figure 3C, D). To determine whether ERK1/2 could mediate the
proliferative effect of epoxypukalide, a specific pharmacological
inhibitor of ERK1/2 (PD98059) was used and its effect on
epxypukalide-b-cell proliferation was examined using [3H]thymi-
dine incorporation. PD98059 decreased the proliferation induced
by epoxypukalide to basal levels (Figure 3E), showing that this
pathway is involved in epoxypukalide-induced b-cell proliferation.
Epoxypukalide Induces Expression of Cell Cycle
Activators
To further investigate the mechanisms by which epoxypkalide
induces b-cell proliferation, we performed western-blots for the
proteins involved in pRb phosphorylation in G1/S (cyclin D1,
cyclin D2, cyclin D3, cdk4, cyclin E and cdk2) in rat islets in the
presence or absence of epoxypukalide. Of the six tested proteins,
only cyclin D2 and cyclin E were up-regulated, showing ,15%
Figure 2. Epoxypukalyde induces b-cell proliferation in primary rat islets. Primary cultures of rat islets were treated with 0.1 mM
epoxypukalide, pukalide, leptolide, (Z)-deoxypukalide or vehicle (Ø) for 24 h. Cell proliferation was measured by [3H]thymidine incorporation as
described in Methods section (N = 6 in triplicate) (*p,0.05) (A). Dose-dependence experiments to test epoxypukalide effectiveness in cell proliferation
in rat islets (N = 6–12 in triplicate). Proliferation was measured by [3H]thymidine incorporation (B). Representative pictures of primary islet cell cultures
treated with 0.1 mM epoxypukalide for 24 h, sections were stained for insulin (green) and BrdU (red). Arrows indicate BrdU-positive b-cells (C).
Quantification of the percentage of BrdU-positive b-cells (N = 6) (*p,0.05) (D).
doi:10.1371/journal.pone.0052862.g002
Figure 3. Activation of signalling pathways by epoxypukalyde
in primary rat islets. Representative western-blot illustrating the
effect of epoxypukalide on AKT proliferation pathway (A). Quantifica-
tion of pAKT/AKT western-blots (N = 4) (B). Representative western-blot
illustrating activation of ERK1/2 pathway (C). Quantification of pERK/ERK
western-blots (N = 4) (D). Cell proliferation was induced with epoxypu-
kalide (Epox) in rat islets pretreated in the presence of PD98059 (PD)
(inhibitor or ERK1/2 pathway) or vehicle (DMSO). b-cell proliferation was
measured by [3H]thymidine incorporation assay and compared to
control (vehicle-treated islets) (N = 3 in triplicate) (E). (*p,0.05).
doi:10.1371/journal.pone.0052862.g003
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Figure 4. Epoxypukalide induces expression of cell cycle activators. Primary cultures of rat islets were treated with epoxypukalide (Epox) or
vehicle. Representative western-blots of cyclin D1, cyclin D2, cyclin D3, cdk4, cyclin E and cdk2 (A). Densitometric analysis of western-blots (N = 3–10)
(B). (*p,0.05).
doi:10.1371/journal.pone.0052862.g004
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more expression in epoxypukalide-treated islets compared to
control islets (Figure 4A, B).
Epoxypukalide Protects Basal and Cytokine-induced b-
cell Death
To investigate the effects of epoxypukalide on b-cell survival, we
performed a dose response evaluation of epoxypukalide, using
concentrations from 0.01–1 mM. We tested cell death using
caspase 3 activation detected by western-blot. Only 0.1 mM
showed a significant decrease in cell death (Figure 5A, B), thus, for
following experiments involving beta-cell death we have used
0.1 mM. To confirm epoxypukalide effect on beta-cell death we
performed TUNEL/insulin staining on sections of rat islets that
were previously exposed to epoxypukalide and their untreated
control. After quantification of TUNEL+insulin+ cells, we
detected 40% lower basal b-cell death in epoxypukalide treated
islets than in control islets (Figure 5C, D). To test epoxypukalide-
protective effect in conditions of stress for the pancreatic islets, we
treated rat islets with cytokines (CK), in the presence or absence of
epoxypukalide, and we determined activation of the apoptotic
pathway using caspase-3 activation. Islets treated with CK showed
80% increase in cleaved-caspase 3 compared to control, this effect
was reverted when islets were treated with 0.1 mM epoxypukalide
(Figure 5E, F).
Epoxypukalyde does not Impair b-cell Function
Finally, we tested whether epoxypukalide alters b-cell function.
To this end we performed glucose-stimulated insulin secretion on
epoxypukalide-treated rat islets to check for b-cell function
in vitro. Insulin secretion after glucose overload was completely
Figure 5. Epoxypukalide protects basal and cytokine-induced b-cell death. Representative western-blot illustrating cell death protection
mediated by epoxypukalide in a dose-dependent manner (A). Densitometric analysis of western-blots (N = 4) (B). Representative pictures of primary
cultures of rat islets treated with epoxypukalyde (Epox) for 24 h, sections were stained for insulin (red) and TUNEL (green) and arrows indicate TUNEL-
positive b-cells (C). Quantification of the percentage of TUNEL-positive b-cells (N = 6) (D). Representative western-blot illustrating the prosurvival
effect of epoxypukalide (E). Densitometric analysis of western-blots (N = 5) (F). (#,&,*p,0.05).
doi:10.1371/journal.pone.0052862.g005
Figure 6. Epoxypukalyde does not impair b-cell function. Glucose-stimulated insulin secretion was performed in 0.1 mM epoxypukalide- or
vehicle-treated rat islets as described in Methods section. 5.5 mM glucose (white bar) and 22 mmol/L glucose (black bar). Experiments were
performed in triplicate (N = 9) (A). Insulin content was measured in islets treated with different concentrations of epoxypukalide (0.01–1 mM) (N = 5 in
triplicate) (B) (*p,0.05).
doi:10.1371/journal.pone.0052862.g006
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normal (Figure 6A). Furthermore we have measured insulin
content in control islets and epoxypukalide- treated islets, finding
that there are not significant differences between epoxypukalide-
treated and control islets (Figure 6B). Both results support that
there is not deleterious effect of epoxypukalide on b-cell function.
Discussion
Search for new molecules to preserve functional b-cell mass is
important for diabetes. Research groups and pharmaceutical
companies are involved in the chase of new molecules that can
induce b-cell proliferation and/or enhance b-cell survival; their
searches are based on the detection of activation of signalling
pathways involved in b-cell death or b-cell proliferation [17,18].
The interaction between chemists that purify and identify new
compounds and biologists who test their function is essential for
the discovery of new treatments.
Accordingly to the structures of compounds 1–4 and the
proliferation results, it can be observed that although they possess
the same carbon skeleton, differences in their functionalizations
are critical to induce proliferation in primary cell cultures. From
comparison of epoxypukalide (1) and leptolide (4) it can be
deduced that the presence of a methyl ester instead of the alhdeyde
group at C-18 is a key to the potency of furanocembranolides. Also
from the observation of epoxypukalide (1), pukalide (2) and (Z)-
deoxypukalide (3) it can be deduced that epoxydation, especially at
C-112C-12, is crucial to show proliferative activity in primary cell
cultures.
From the dose-dependence studies we have learned that 0.1 mM
is the optimal concentration to induce beta-cell proliferation and
to inhibit beta-cell death. This should be the reference concen-
tration to design in vivo experiments in rodents.
Two of the most relevant pathways involved in b-cell
proliferation (AKT and ERK1/2) were studied. Analysis of these
two pathways indicated that epoxypukalide did activate ERK1/2
pathway. Some growth factors have shown to induce b-cell
proliferation through ERK1/2 signalling including HGF [19],
insulin and IGF1 (insulin growth factor-1) [5].
It has been shown that G1/S interphase is essential in the
regulation of b-cell cycle proliferation. Cyclin D2 and E,
individually, have been shown previously to induce b-cell
replication under the stimulus of several mitogens including high
glucose, GH (growth hormone), PRL (prolactin) and PTHrP
[5,7,8,9,10,11,12,13]. Cyclin D2 joins to cdk4 and cyclin E to cdk2
maintaining pRb phosphorylation in different residues. We can
argue that since both cyclins are upregulated by epoxypukalide, it
induces a synergistic effect responsible to maintain beta-cell
proliferation, even though their expression levels increase mod-
estly.
CK (cytokine)-induced b-cell apoptosis is a hallmark of diabetes
[1,20,21,22]. Our experiments showed epoxypukalide protects b-
cells from basal and CK-induced apoptosis. Other small molecules
have shown similar effects on protection of CK-induced b-cell
apoptosis [18], but their proliferative capability was not tested. It is
important to expand b-cell mass in order to have an efficient
control of glucose homeostasis in diabetes. In support of this
notion, Zhao et al. showed that diabetic mice (leptin receptor null-
db/db) treated with a sphingosine 1-phosphate receptor modula-
tor (FTY720) counteracted hyperglycemia by induction of b-cell
proliferation and b-cell mass expansion [23].
Increased b-cell proliferation may involve loss of differentiation
and cell function failure. Thus, we performed glucose-stimulated
insulin secretion on epoxypukalide-treated rat islets to check for b-
cell function in vitro. Insulin production and secretion after
glucose overload was completely normal, meaning that there is not
deleterious effect of epoxypukalide on b-cell function. This is
important in order of a possible use of this compound in the
treatment of diabetes. In this direction, Grote et al. showed that
epoxypukalide was not cytotoxic for L-929 (murine fibrosarcoma)
or K-562 (human erythroleukemic cell line) [16]. Their results
sustain that epoxypukalide has not adverse effects on other cell
types.
In conclusion, our study supports that epoxypukalide is a
potential drug for the treatment of diabetes, further work in
granted in order to study its in vivo effects.
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